Among the top five factors secreted by CAFs in lung cancer, FST surprisingly emerged as a critical player in rescuing cancer cells from EGFR-TKI-induced toxicity, and thus represents a potential target to combat drug resistance in NSCLC (Figure 3A). Here, FST is linked to lung carcinoma.